INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 242 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $104,516 | +11.3% | 1,526 | +12.5% | 0.02% | +6.2% |
| Q1 2024 | $93,904 | -9.3% | 1,357 | -6.1% | 0.02% | -15.8% |
| Q4 2023 | $103,491 | +57.2% | 1,445 | +14.3% | 0.02% | +35.7% |
| Q3 2023 | $65,842 | +22.2% | 1,264 | +48.5% | 0.01% | -12.5% |
| Q2 2023 | $53,885 | +84.6% | 851 | +57.9% | 0.02% | +77.8% |
| Q1 2023 | $29,187 | +5.3% | 539 | +2.9% | 0.01% | 0.0% |
| Q4 2022 | $27,730 | +38.6% | 524 | +23.6% | 0.01% | -10.0% |
| Q3 2022 | $20,000 | -20.0% | 424 | -2.5% | 0.01% | -33.3% |
| Q2 2022 | $25,000 | -70.9% | 435 | -69.1% | 0.02% | -65.1% |
| Q1 2022 | $86,000 | – | 1,407 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 360,000 | $11,502,000 | 2.65% |
| Redmile Group, LLC | 610,171 | $19,495,000 | 1.60% |
| Pier Capital, LLC | 257,256 | $8,219,000 | 1.18% |
| WALL STREET ASSOCIATES | 358,857 | $11,465,000 | 1.08% |
| SENZAR ASSET MANAGEMENT, LLC | 161,300 | $5,154,000 | 0.88% |
| Rhenman & Partners Asset Management AB | 206,000 | $6,582,000 | 0.79% |
| EAM Investors, LLC | 152,389 | $4,869,000 | 0.57% |
| EDMOND DE ROTHSCHILD (SUISSE) S.A. | 50,000 | $1,598,000 | 0.51% |
| Visium Asset Management, LP | 1,051,479 | $33,595,000 | 0.48% |
| SPHERA FUNDS MANAGEMENT LTD. | 128,000 | $4,090,000 | 0.40% |